2006
DOI: 10.1152/ajpgi.00239.2005
|View full text |Cite
|
Sign up to set email alerts
|

Involvement of Toll-like receptor 4 in acetaminophen hepatotoxicity

Abstract: The objective of this study was to determine whether Toll-like receptor 4 (TLR4) has a role in alcohol-mediated acetaminophen (APAP) hepatotoxicity. TLR4 is involved in the inflammatory response to endotoxin. Others have found that ethanol-mediated liver disease is decreased in C3H/HeJ mice, which have a mutated TLR4 resulting in a decreased response to endotoxin compared with endotoxin-responsive mice. In the present study, short-term (1 wk) pretreatment with ethanol plus isopentanol, the predominant alcohols… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
44
0

Year Published

2006
2006
2014
2014

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 64 publications
(48 citation statements)
references
References 67 publications
4
44
0
Order By: Relevance
“…It is noteworthy that APAP intoxication in wild-type mice induced macrovacuolar steatosis in some hepatocytes (Fig. 2C), as described previously in humans and mice (Yohe et al, 2006;Begriche et al, 2011). Moreover, APAP intoxication aggravated steatosis in obese mice, in particular in ob/ob mice (Fig.…”
Section: Preliminary Investigations In Lean and Obese Micesupporting
confidence: 84%
“…It is noteworthy that APAP intoxication in wild-type mice induced macrovacuolar steatosis in some hepatocytes (Fig. 2C), as described previously in humans and mice (Yohe et al, 2006;Begriche et al, 2011). Moreover, APAP intoxication aggravated steatosis in obese mice, in particular in ob/ob mice (Fig.…”
Section: Preliminary Investigations In Lean and Obese Micesupporting
confidence: 84%
“…-/-mice are resistant to APAP toxicity (50). The modeling and prediction of human variability in DILI in animal models remains a major goal for safe drug development.…”
Section: O V E M B E R -D E C E M B E R 2 0 1 0 F a S T I N G I N H Imentioning
confidence: 99%
“…Activation of TLR4 can cause liver injury in several pathological processes such as hemorrhagic shock, hepatic ischemia/ reperfusion injury, alcohol-induced liver injury and hepatic failure. [33][34][35][36][37] Inhibition of TLR4 with a TLR4 antagonist or recombinant soluble forms of extracellular TLR4 domain and MD-2 can attenuate myocardial ischemia-reperfusion injury, dampen lipopolysaccharide-induced pulmonary inflammation in mice and have anti-inflammatory effects in murine models of inflammatory bowel disease. [38][39][40] Our finding of elevated expression of TLR4 in hepatocytes may have a role in the pathogenesis of CHB while little effect on the inhibition of replication of HBV, TLR4 antagonist may be helpful in the treatment of CHB.…”
Section: Discussionmentioning
confidence: 99%